|drug1238||Exercise training group Wiki||0.45|
|drug1838||Local standard of care Wiki||0.45|
|drug1168||Electronic survey Wiki||0.45|
|D051436||Renal Insufficiency, Chronic NIH||0.77|
|D051437||Renal Insufficiency, NIH||0.52|
|D007676||Kidney Failure, Chronic NIH||0.40|
There are 5 clinical trials
To understand the impact of COVID-19 restrictions on the wellbeing, quality of life and physical activity of people with end-stage renal disease, currently dialysing in-centre versus at home in the UK and their experience of telemedicine.
Description: Participants will be asked during a qualitative interview about the effect of COVID-19 restrictions on their; well-being, quality of life and physical activity and sedentary behavioursMeasure: Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours Time: Day 1
Description: Participants will be asked during a qualitative interview about their perceptions and experiences of telemedicineMeasure: Thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the COVID-19 restrictions in the UK Time: Day 1
Data show that the coronavirus disease 2019 (COVID-19) symptoms can be severe in 4% and 3% of the adolescents aged 11-15 years and ≥ 16 years, respectively. In addition, the prevalence of chronic diseases among adolescents has increased in the last years. About 20% of the adolescents have some chronic disease, resulting in increased morbidity and mortality. In march, 2020, the quarantine was officially implemented in Sao Paulo, while elective medical appointments for adolescents with chronic disease were temporarily suspended. To mitigate the deleterious effect of the social isolation on physical and mental health among these patients, this study aims to test the effects of an online, home-based, exercise training program.
Description: Semi structured interviewMeasure: Safety and efficacy of a home-based exercise training program Time: From baseline to 3 months of follow-up
Description: Semi structured interviewMeasure: Patients perceptions during social isolation Time: From baseline to 3 months of follow-up
Description: Quality of life will be assessed by means of Pediatric Quality of Life inventory (PedsQLTM 4.0)Measure: Adolescents quality of life Time: From baseline to 3 months of follow-up
Description: Will be assessed by means of a visual analog scale (from 0 - no disease activity) to 10 - maximum disease activity).Measure: Disease activity Time: From baseline to 3 months of follow-up
Description: Will be assessed using the visual analog scale from 0 (very good condition) to 10 (very poor condition).Measure: Disease overall assessment Time: From baseline to 3 months of follow-up
Description: Will be assessed by means of Strengths & Difficulties QuestionnairesMeasure: Strengths and difficulties Time: From baseline to 3 months of follow-up
The coronavirus (COVID-19) pandemic has created a significant strain on health care resources across the world for managing critically ill patients. Emerging reports from China, South Korea and Italy have reported varying incidence of acute kidney (AKI) ranging from 5-15% with a mortality of 60-80% however there is no systematic assessment of the risk factors, recognition, course and outcomes in patients with and without kidney disease whose course is complicated by AKI1-4. Patients with underlying CKD, immunosuppressed patients with renal transplants and ESKD patients are at high risk for COVID-19 infection and there is limited information on the effect of COVID-19 on the course and outcomes of these patients. The requirement for renal support including IHD, CRRT and sorbent based therapies has been variable and has contributed to the intense pressure on the nephrology and critical care providers for delivering these therapies. As the COVID-19 pandemic expands in the USA and abroad, there is an intense need to understand the epidemiology of the disease and the resources needed for renal support to inform clinical management and public health interventions. In this study, the investigators aim to investigate health care facilities across the world (hospital wards, ICU, outpatient clinics, nursing homes, healthcare centers) to draw a global picture of incidence, risk factors, resources available for treatment and prognosis of acute and chronic kidney disease in patient with COVID 19 confirmed infection. The aim is to identify trends in patients with acute and chronic kidney disease, determine its incidence, treatment and outcomes in different settings across the world. This information will be used to develop and implement educational tools and resources to prevent deaths from AKI and progression of CKD in this and following pandemics.
Description: Meeting of at least one of the modified KDIGO Criteria Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours Increase or decrease in serum creatinine > 50% from reference in 7 days Urine output < 400 ml/dayMeasure: AKI incidence Time: from hospital admission through hospital discharge upto 24 weeks
Description: initiation of intermittent hemodialysis, continuous hemodialysis or peritoneal dialysis during the hospital stayMeasure: Dialysis requirement Time: through study completion upto 1 year from enrollment
Description: Deaths during primary hospitalizationMeasure: hospital mortality Time: through study completion within 1 year
Description: C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent Percentage of patinets with renal functioanl recovery based on serum creatinien levels classfied as C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependentMeasure: Renal functional recovery Time: Assessed at at 3, 6 and 12 months from enrollment at hospital admission
Description: EQL5D scale and SH8 scales completed at 3, 6 and 12 months post enrollmentMeasure: Functional status Time: questionnaires to be completed at 3, 6 and 12 months from enrollment at hospital admission
Description: Number of days patient is in the hospital and ICU and is managed with ventilators, dialysis or other extracorporeal organ support e.g. ECMO during the hospital stayMeasure: Resource utilization Time: Within 1 year of enrollment for primary hospitalization
The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.
1. Purpose: To confirm the changes in lifestyle due to differences in perceptions of infectious disease risk after the COVID-19 pandemic, decrease in exposure levels of environmentally hazardous chemicals and changes in indicators related to chronic kidney disease 2. Methods: - Survey on health risk awareness and lifestyle for COVID-19 - Blood and urine tests for exposure to environmentally hazardous chemicals - Collection of hospital clinical data utilization for indicators related to chronic kidney disease 3. Clinical endpoints: - Verification of differences in health risk perception level and lifestyle changes - Verification of changes in lifestyle changes and exposure to environmentally hazardous chemicals - Verification of changes in indicators related to kidney disease according to changes in exposure to environmentally hazardous chemicals 4. Statistical methods: chi-square test, independent mean comparison t-test, ANOVA test, regression analysis
Description: Collecting and organizing survey data Calculation of technical statistics on exposure to major environmental hazards Identification of determinants affecting the exposure level of environmentally hazardous substancesMeasure: Identification of environmental hazard exposure levels and influencing factors Time: From initial recruitment to after 21 (+/- 3) months
Description: Analysis of correlation of kidney disease occurrence according to exposure to harmful substances Identify the possibility of health effects from exposure to environmentally harmful factors such as disease prevalence, glomerular filtration rate, and urine protein/creatinine ratio according to the definition of chronic kidney disease.Measure: Relationship between exposure and health related behavior change Time: From initial recruitment to after 21 (+/- 3) months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports